Palifermin vs Ac-SDKP
Head-to-head comparison of Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) and Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Palifermin | Ac-SDKP |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) | N-Acetyl-Seryl-Aspartyl-Lysyl-Proline |
| Molecular Weight | 16.3 kDa | 432.4 Da |
| Half-Life | 4–6 hours | minutes |
| Amino Acids | 140 | 4 |
| Typical Dose | 60 µg/kg/day | 10–100 µg/kg/day in pre-clinical studies |
| Route | Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 250 | 180 |
| Research Status | Clinical | Pre-clinical |
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
Ac-SDKP Benefits
- ✓anti-inflammatory tissue remodeling
- ✓fibroblast modulation
- ✓microvascular protection
- ✓faster regenerative signaling
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
Ac-SDKP Dosing
Research-only systemic microdoses|short daily dosing in animal models|route varies by study
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
Ac-SDKP Side Effects
- ⚠GI upset
- ⚠hypotension at high exposure
- ⚠unknown long-term safety
Research Overview
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
Ac-SDKP
Ac-SDKP has literature in tissue remodeling, angiogenesis, and organ repair models. Its strongest evidence is pre-clinical, where it modulates inflammation and fibrosis during healing.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.